A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Neoplasm Malignant|Renal Cell Carcinoma|Hormone Receptor Positive Breast Carcinoma|Metastatic Castration-resistant Prostate Cancer|Colorectal Cancer
Interventions: DRUG: XL092|DRUG: Atezolizumab|DRUG: Avelumab
Sponsor: Exelixis